Phase Ia/Ib and Potential Phase IIa Study of the Safety and Pharmacokinetics of NOX66 Both as a Monotherapy and in Combination With Carboplatin in Patients With Refractory Solid Tumours
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 11 Jan 2018
At a glance
- Drugs Idronoxil (Primary) ; Carboplatin
- Indications Advanced breast cancer; Head and neck cancer; Lung cancer; Ovarian cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Noxopharm
- 07 Jan 2018 Planned End Date changed from 1 Apr 2019 to 1 Dec 2019.
- 07 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 08 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.